bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Financial Statements and Exhibits

bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Financial Statements and Exhibits
Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

bluebird bio, Inc. Exhibit
EX-99.1 2 blue-ex991_6.htm EX-99.1 blue-ex991_6.htm   Exhibit 99.1   bluebird bio Appoints Alison Finger as Chief Commercial Officer   Cambridge,…
To view the full exhibit click here

About bluebird bio, Inc. (NASDAQ:BLUE)

bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

An ad to help with our costs